PMC:7195088 / 46225-46478 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"1395","span":{"begin":89,"end":97},"obj":"Species"},{"id":"1400","span":{"begin":167,"end":176},"obj":"Species"},{"id":"1401","span":{"begin":212,"end":221},"obj":"Species"},{"id":"1403","span":{"begin":191,"end":201},"obj":"Chemical"},{"id":"1408","span":{"begin":80,"end":88},"obj":"Disease"}],"attributes":[{"id":"A1395","pred":"tao:has_database_id","subj":"1395","obj":"Tax:9606"},{"id":"A1400","pred":"tao:has_database_id","subj":"1400","obj":"Tax:11520"},{"id":"A1401","pred":"tao:has_database_id","subj":"1401","obj":"Tax:11520"},{"id":"A1403","pred":"tao:has_database_id","subj":"1403","obj":"MESH:C086979"},{"id":"A1408","pred":"tao:has_database_id","subj":"1408","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Other antiviral agents currently being investigated in RCT for the treatment of COVID-19 patients are favipiravir, an RNA-dependent RNA polymerase inhibitor with anti-influenza activity, and umifenovir, and anti-influenza membrane fusion inhibitor [29]."}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T83","span":{"begin":118,"end":121},"obj":"Body_part"},{"id":"T84","span":{"begin":132,"end":135},"obj":"Body_part"}],"attributes":[{"id":"A83","pred":"fma_id","subj":"T83","obj":"http://purl.org/sig/ont/fma/fma67095"},{"id":"A84","pred":"fma_id","subj":"T84","obj":"http://purl.org/sig/ont/fma/fma67095"}],"text":"Other antiviral agents currently being investigated in RCT for the treatment of COVID-19 patients are favipiravir, an RNA-dependent RNA polymerase inhibitor with anti-influenza activity, and umifenovir, and anti-influenza membrane fusion inhibitor [29]."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T258","span":{"begin":80,"end":88},"obj":"Disease"},{"id":"T259","span":{"begin":167,"end":176},"obj":"Disease"},{"id":"T260","span":{"begin":212,"end":221},"obj":"Disease"}],"attributes":[{"id":"A258","pred":"mondo_id","subj":"T258","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A259","pred":"mondo_id","subj":"T259","obj":"http://purl.obolibrary.org/obo/MONDO_0005812"},{"id":"A260","pred":"mondo_id","subj":"T260","obj":"http://purl.obolibrary.org/obo/MONDO_0005812"}],"text":"Other antiviral agents currently being investigated in RCT for the treatment of COVID-19 patients are favipiravir, an RNA-dependent RNA polymerase inhibitor with anti-influenza activity, and umifenovir, and anti-influenza membrane fusion inhibitor [29]."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T269","span":{"begin":177,"end":185},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T270","span":{"begin":222,"end":230},"obj":"http://purl.obolibrary.org/obo/UBERON_0000158"}],"text":"Other antiviral agents currently being investigated in RCT for the treatment of COVID-19 patients are favipiravir, an RNA-dependent RNA polymerase inhibitor with anti-influenza activity, and umifenovir, and anti-influenza membrane fusion inhibitor [29]."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T560","span":{"begin":6,"end":22},"obj":"Chemical"},{"id":"T561","span":{"begin":102,"end":113},"obj":"Chemical"},{"id":"T562","span":{"begin":132,"end":156},"obj":"Chemical"},{"id":"T563","span":{"begin":147,"end":156},"obj":"Chemical"},{"id":"T564","span":{"begin":191,"end":201},"obj":"Chemical"},{"id":"T565","span":{"begin":238,"end":247},"obj":"Chemical"}],"attributes":[{"id":"A560","pred":"chebi_id","subj":"T560","obj":"http://purl.obolibrary.org/obo/CHEBI_22587"},{"id":"A561","pred":"chebi_id","subj":"T561","obj":"http://purl.obolibrary.org/obo/CHEBI_134722"},{"id":"A562","pred":"chebi_id","subj":"T562","obj":"http://purl.obolibrary.org/obo/CHEBI_37416"},{"id":"A563","pred":"chebi_id","subj":"T563","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A564","pred":"chebi_id","subj":"T564","obj":"http://purl.obolibrary.org/obo/CHEBI_134730"},{"id":"A565","pred":"chebi_id","subj":"T565","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"}],"text":"Other antiviral agents currently being investigated in RCT for the treatment of COVID-19 patients are favipiravir, an RNA-dependent RNA polymerase inhibitor with anti-influenza activity, and umifenovir, and anti-influenza membrane fusion inhibitor [29]."}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T14","span":{"begin":222,"end":237},"obj":"http://purl.obolibrary.org/obo/GO_0061025"}],"text":"Other antiviral agents currently being investigated in RCT for the treatment of COVID-19 patients are favipiravir, an RNA-dependent RNA polymerase inhibitor with anti-influenza activity, and umifenovir, and anti-influenza membrane fusion inhibitor [29]."}

{"project":"LitCovid-sentences","denotations":[{"id":"T365","span":{"begin":0,"end":253},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Other antiviral agents currently being investigated in RCT for the treatment of COVID-19 patients are favipiravir, an RNA-dependent RNA polymerase inhibitor with anti-influenza activity, and umifenovir, and anti-influenza membrane fusion inhibitor [29]."}

{"project":"2_test","denotations":[{"id":"32360444-32147628-22369769","span":{"begin":249,"end":251},"obj":"32147628"}],"text":"Other antiviral agents currently being investigated in RCT for the treatment of COVID-19 patients are favipiravir, an RNA-dependent RNA polymerase inhibitor with anti-influenza activity, and umifenovir, and anti-influenza membrane fusion inhibitor [29]."}